Novartis, Cepheid Hope to Improve Bcr-Abl Transcript Monitoring in Gleevec-Treated CML Patients | GenomeWeb

This article has been clarified to note that Novartis discovered the gene marker linked to liver toxicities associated with lumiracoxib, not Novartis' diagnostics unit.

By Turna Ray

Cepheid and Novartis are collaborating on the development of a test for monitoring Bcr-Abl gene transcripts, which will help doctors more reliably manage Philadelphia chromosome-positive chronic myelogenous leukemia patients treated with Novartis' oncologic Gleevec.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.